# Q32 Bio share price today (Q32 Bio Inc., QTTB)

> Q32 Bio Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. QTTB · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/qttb

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $8.97 (+296.9% in a year)
- P/E: 4.0×, against its own history
- Revenue (Dec 2025): $53.7 M
- Profit (Dec 2025), incl. one-off: $57.7 M (one-off item, see below)
- Operating margin: 85.4%
- ROE: 71%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Q32 Bio share price today? Q32 Bio Inc.'s share price was $8.97 at the close on 4 November 2026. That is 3.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $16, and at that close it sat 50% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 10 weeks running. Over the last 1 year the share price moved +237% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 28 August 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Q32 Bio pay? Q32 Bio Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Q32 Bio on? Q32 Bio is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Q32 Bio profitable? Q32 Bio Inc. earned $57.7 M of net profit in the Dec 2025 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. Full-year FY25 profit was $29.8 M. That is 107.4% of the quarter's revenue. The same quarter a year earlier lost $6.8 M. 7 of the last 8 reported quarters were loss-making. Read this profit with care: at $57.7 M it is bigger than the quarter's whole revenue of $53.7 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a 85.4% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Q32 Bio make, and is it growing? Q32 Bio Inc. reported $53.7 M of revenue in the Dec 2025 quarter. Over 3 years it has grown 100.7% a year on average. The last full year, FY25, came in at $53.7 M. The quarterly figures for FY22 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. ## How much of every $100 of sales does Q32 Bio keep? Q32 Bio Inc.'s operating margin was 85.4% in the Dec 2025 quarter. Over the last four quarters it has moved +335.6 percentage points. Across 3 years it has been between −589.8% and 725.5%. The latest quarter is within that range. Why the margin moved: operating margin changed +335.6 percentage points on the year while gross margin changed +262.2 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Q32 Bio's profit turning into cash? Q32 Bio Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $33.5 M of cash, against $29.8 M of profit. After null of spending on assets, free cash was −$33.5 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Q32 Bio's cash go? Q32 Bio Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.5 M on assets over the last 2 years. Averaged over those years that is 2.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.5 M over the last 2 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Q32 Bio's P/E ratio, and how does it compare with its own history? Q32 Bio Inc.'s P/E is 4.0×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Q32 Bio business getting better or worse? Q32 Bio Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Q32 Bio earn on its capital? Q32 Bio Inc. earned a ROE of 71% in FY25. Its return on capital used (ROIC) is 19.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 55.5% net margin and 0.87× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 55.5% net margin × 0.87× asset turnover × 1.47× leverage (assets divided by equity) ≈ 71.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 22.8% − 3.8% = +19.0 percentage points. The 3.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does Q32 Bio have too much debt? Q32 Bio Inc. has total debt of $5.3 M against shareholder equity of $106 M as of Jun 2026, so its debt is 0.05× its equity, which is very little. Year by year, that ratio went from 0.22 in FY21 to 0.37 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Q32 Bio shareholding pattern? 44.4% of Q32 Bio Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Q32 Bio from balance-sheet trouble? For Q32 Bio Inc., the Z-score is 3.36. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.36 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Q32 Bio rank in its industry? There is no score against its industry: Q32 Bio Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Q32 Bio compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Q32 Bio in size? Q32 Bio is the 178th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: SAB Biotherapeutics, Inc., Fulcrum Therapeutics, Inc. and Inhibikase Therapeutics, Inc. Just below it: Bicycle Therapeutics plc, Lineage Cell Therapeutics, Inc. and Fate Therapeutics, Inc. ### Biotechnology companies close in size

1. [SAB Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/sabs) $289 million
2. [Fulcrum Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/fulc) $288 million
3. [Inhibikase Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ikt) $285 million
4. Q32 Bio Inc. $267 million
5. [Bicycle Therapeutics plc](https://www.sectoralpha.in/us/stocks/bcyc) $261 million
6. [Lineage Cell Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/lctx) $260 million
7. [Fate Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/fate) $250 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Arqit Quantum Inc.](https://www.sectoralpha.in/us/stocks/arqq) $261 million · Software - Infrastructure
2. [NACCO Industries, Inc.](https://www.sectoralpha.in/us/stocks/nc) $261 million · Thermal Coal
3. Q32 Bio Inc. $261 million
4. [Anika Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/anik) $260 million · Drug Manufacturers - Specialty & Generic
5. [BK Technologies Corporation](https://www.sectoralpha.in/us/stocks/bkti) $259 million · Communication Equipment

## What else do people ask about Q32 Bio? ### What were Q32 Bio's latest quarterly results? Q32 Bio Inc. reported revenue of $53.7 M and net profit of $57.7 M for the Dec 2025 quarter. Earnings per share were $4.59. The operating margin was 85.4% (as of 4 November 2026). ### What is Q32 Bio's market cap? Q32 Bio Inc.'s market capitalisation is $267 M at a stock price of $8.97. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Q32 Bio performing? Q32 Bio Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 10 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Q32 Bio's stock price go up? This page does not forecast Q32 Bio Inc.'s stock price. What it shows instead: the stock price is $8.97. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What is Q32 Bio's capex? Q32 Bio Inc. spent $2.5 M on capital expenditure (new plants, machines and other long-term assets) over the last 2 years, worked out from the change in fixed assets plus depreciation. In FY23 alone that was $5.0 K (as of 4 November 2026). ### Where is Q32 Bio in its business cycle? Q32 Bio Inc.'s FY25 operating margin was 31.5%, against a 3-year range of −589.8% to 725.5%: the middle of its own range, neither a peak nor a low. The latest quarter was 85.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Q32 Bio story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Q32 Bio a stock worth studying right now? What the numbers show: Q32 Bio Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.